Faculty Profile

Dale  Johnson, PharmD, PhD, DABT

Dale Johnson, PharmD, PhD, DABT

  • Adjunct Professor, Environmental Health Sciences
  • 1415 Washington Heights
  • Ann Arbor, Michigan 48109-2029

Dale Johnson has over 30 years of experience as a research and development scientist, manager, executive, and entrepreneur in the biopharmaceutical field working in large pharmaceutical and biotech companies and several start-ups. Currently he is President & CEO of Emiliem, Inc. a private biopharmaceutical company. Prior to Emiliem, he served as VP Drug Assessment & Development and VP Preclinical Development at Chiron Corporation, VP Preclinical & Predictive Development at Eos Biotechnology, Sr. Director Toxicology Research & Preclinical Safety at the Medical Research Division of American Cyanamid (Lederle Laboratories), Scientific Director of the Experimental Toxicology Division at International Research and Development Corp., and Sr. Research Toxicologist at Hoechst-Roussel Pharmaceuticals Inc. He was Founder, Chief Scientific Officer & President of ddplatform LLC, a consulting firm in computational toxicology and a technology incubator. Dr. Johnson has been directly involved in the advancement of over 100 compounds from discovery into clinical development of which sixteen have become marketed health care medicinal products and vaccines in the US, Canada, Europe, and Japan. He has personally led multinational projects involving small molecules, recombinant proteins, monoclonal antibodies, gene therapy, photodynamic therapeutics, vaccines, and vaccine adjuvants. In addition, he has been actively involved in portfolio evaluation and decision making in his own and collaborating companies as well as a consultant and advisory board member for outside groups. He has been active in industry-government working groups, consulted on asset evaluation for venture capital firms, served as an expert for litigation work, and is an inventor on several issued and pending patents. He received his PhD degree in Toxicology from the University of Michigan where he was an AFPE Fellow. Prior to his PhD work, he received B.S. and Pharm.D. degrees from the University of Michigan College of Pharmacy and completed a residency at UM Medical Center receiving the Squibb National Resident of the Year Award for his work on adverse drug reactions. He is a Board Certified Toxicologist and is a member of industry and government advisory boards and editorial boards for scientific journals and book series. Dr. Johnson was a member of the initial Green Ribbon Science Panel for the State of California green chemistry initiatives and is a member of the USEPA Board of Scientific Counselors subcommittee on Chemical Safety and Sustainability. He is an Adjunct Professor at the University of California, Berkeley, where he teaches computational toxicology, a course in drug discovery & development, and lectures in pharmacogenomics.

  • Book: Computational Systems Pharmacology and Toxicology, Eds. Dale E. Johnson and Rudy J. Richardson. Royal Society of Chemistry, Cambridge, UK. (2017)

    Authored Chapters in above book

  • Dale E. Johnson. Systems Biology Approaches in Pharmacology and Toxicology. (2017) Chapter 1. pp. 1-18.
  • Dale E. Johnson and Ann M. H. Heslin. (2017) Chapter 2. Databases Facilitating Systems Biology Approaches in Toxicology. pp. 19-35.
  • David Faulkner, Leah K. Rubin Shen, Vanessa Y. De La Rosa, Dale E. Johnson, Rachel Hemingway, Richard V. Williams, Philip N. Judson, John Arnold and Chris D. Vulpe. (2017) Chapter 3. Tools for Green Molecular Design to Reduce Toxicological Risk. pp. 36-59. 
  • Dale E. Johnson. (2017) Chapter 11. Network Pharmacology Research Approaches for Herbal medicines. pp. 261-278.
  • Dale E. Johnson and Kit Wun Kathy Cheung. (2017) Chapter 12. Chemical- Disease Category Linkage (CDCL): Computational Methods Linking Traditional Chinese Medicines and Western therapeutics. pp. 279-299.
  • Dale E. Johnson and Rudy J. Richardson. (2017) Chapter 13. Educational Programs for Computational Toxicology. pp. 300-323.
  • Burrage, L.C., Q. Sun, S.H. Elsea, M.-M. Jiang, S.C.S. Nagamani, A.E. Frankel, E.Stone, S.E. Alters, D.E. Johnson, S.W. Rowlinson, G. Georgiou, B.H. Lee (2015) Human recombinant arginase enzyme reduces plasma arginase in mouse models of arginase deficiency. Human Molecular Genetics, 24(22) 6417-6427.

  • Schwarzman, M. J. Ackerman, S. Dairkee, S. Fenton, D. Johnson, K. Navarro, G. Osborne, R. Rudel, G. Solomon, L. Zeise, S. Janssen (2015)  Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation. Environ Health Perspectives. 123(12) 1255-1264.

  • Johnson, D.E. (2014) Fast-tracking an orphan drug indication within a broader development project. Expert Opinion Orphan Drugs 2(2) 107-111

  • Felker, D., A. Lynn, S. Wang, D. Johnson (2014) Evidence for a Potential Protective Effect of Carnitine-Pantothenic Acid Co-treatment on Valproic Acid-Induced Hepatotoxicity. Expert Rev Clin Pharmacol 7 (2) 211-218

  • Johnson, D.E. (2013) Fusion of nonclinical and clinical data to predict human drug safety. Exp Rev Clin Pharmacol. 6(2) 185-195.

  • Johnson, D.E.  and G.L. Anderson (2013) Green Chemistry and Toxicology. Chapter 11 in "Green Chemistry and Engineering: A Pathway to Sustainability". Editors: M. Abraham and A.E. Marteel-Parrish. John Wiley & Sons, New York. Pp 325-353.

  • Larson, H., E. Chan, S. Sudarsanam, and  D.E. Johnson. (2012)  Biomarkers. In Computational Toxicology Vol II. Chapter 11,  Methods in Molecular Biology,  Eds. Reisfeld B and Mayeno A.Humana Press, Springer Science, NY, NY. pp. 253-273.

  • Johnson, D.E. and S. Sudarsanam (2012) Molecular challenges in frontloading toxicity testing of anti-cancer drugs in drug discovery. Encyclopedia of Drug Metabolism and Interactions.  Chapter 3. Pp-1-20, Ed. Lyubinov AV, John Wiley & Sons, New York.  DOI:10.1002/9780470921920.edm048

  • Johnson, D.E. (2012) Estimating human cancer risk from rodent carcinogenicity studies: The changing paradigm for pharmaceuticals. J Drug Metab Toxicol. 3 (6) Open Access. http://dx.doi.org/10.4172/2157-7609.1000e114

  • Johnson, D.E. (2012) Predicting drug safety: Next generation solutions. J Drug Metab Toxicol. 3 (2) Open Access http://dx.doi.org/10.4172/2157-7609.1000e106.  
  • Johnson, D.E., S. Subha, B. Jonathan, and S. Sucha. (2012) Translational biology approach to identify causative factors for rare toxicities in humans and animals. Curr Drug Discov Technol . 9(1) 77-80.